Douglass Winthrop Advisors LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 0.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 438,078 shares of the medical research company’s stock after buying an additional 1,076 shares during the period. IQVIA makes up 2.0% of Douglass Winthrop Advisors LLC’s holdings, making the stock its 23rd biggest position. Douglass Winthrop Advisors LLC owned 0.24% of IQVIA worth $103,811,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. First Foundation Advisors boosted its holdings in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after purchasing an additional 43 shares during the last quarter. Invera Wealth Advisors LLC boosted its stake in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after buying an additional 46 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after buying an additional 48 shares in the last quarter. Continuum Advisory LLC increased its stake in shares of IQVIA by 3.3% in the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock worth $325,000 after acquiring an additional 49 shares during the last quarter. Finally, Clear Harbor Asset Management LLC raised its holdings in shares of IQVIA by 1.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after acquiring an additional 50 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Stock Performance
Shares of IQVIA stock opened at $201.82 on Monday. The business has a 50-day simple moving average of $222.67 and a 200-day simple moving average of $227.16. The company has a market cap of $36.63 billion, a PE ratio of 26.49, a P/E/G ratio of 2.08 and a beta of 1.51. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.
Analysts Set New Price Targets
Check Out Our Latest Report on IQV
Insider Transactions at IQVIA
In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.
IQVIA Company Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
- Five stocks we like better than IQVIA
- Using the MarketBeat Dividend Yield Calculator
- C3.ai Advances AI Leadership, Boosting Stock Performance
- 10 Best Airline Stocks to Buy
- 3 Top-Performing U.S.-Traded Emerging Market Stocks in 2024
- Ride Out The Recession With These Dividend Kings
- Disney’s Magic Strategy: Reinventing the House of Mouse
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.